Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
34.50
-0.44 (-1.26%)
At close: Jan 24, 2025, 4:00 PM
35.00
+0.50 (1.45%)
After-hours: Jan 24, 2025, 7:45 PM EST
Viking Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
27
Market Cap
3.84B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
VKTX News
- 1 day ago - Viking Therapeutics: Investors Meeting Reality Of The Obesity Market - Seeking Alpha
- 1 day ago - Why this Weight-Loss Drug Stock Could Gain 200% - Barrons
- 2 days ago - Top 3 Health Care Stocks That Could Blast Off This Quarter - Benzinga
- 3 days ago - What's next for Viking Therapeutics? Here's how the company can scale up. - Market Watch
- 11 days ago - 3 Oversold Biotech Names - Seeking Alpha
- 16 days ago - Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - PRNewsWire
- 18 days ago - Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 18 days ago - Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst - Benzinga